Owkin
Owkin integrates human and artificial intelligence to enhance drug discovery and diagnostics, leveraging multimodal patient data and strategic partnerships with leading biopharma companies.
Services
Owkin provides a range of services leveraging human and artificial intelligence to improve drug development and diagnostics. Their AI engines integrate expertise in AI, biology, and medicine to uncover biological interactions and identify novel drug targets. The company's AI diagnostics are designed to pre-screen for biomarkers and predict outcomes, supporting healthcare providers in making informed treatment decisions. Owkin also offers AI external control arms for early efficacy estimates in clinical trials, inclusion criteria models to enhance patient recruitment, and data-driven covariate adjustment to improve phase III trial success.
Products
Owkin has developed several AI-powered products aimed at enhancing drug discovery and diagnostics. Key products include MSIntuit® CRC, a CE-marked AI diagnostic tool for screening MSI in colorectal cancer, and RlapsRisk® BC, an AI diagnostic tool to assess the risk of relapse in early breast cancer patients. These tools integrate seamlessly into digital pathology workflows. Additionally, Owkin's AI-powered drug discovery engines identify new drug targets and optimize drug positioning, contributing to more effective and tailored treatments.
Technology
Owkin employs advanced technologies including federated learning, which enables collaborative research without sharing data between partners. Their federated learning software, Substra, allows the training and validation of machine learning models on distributed datasets. This technology supports the creation of interpretable AI models for researchers and medical experts, ensuring that AI tools are both effective and understandable. Owkin also emphasizes AI ethics and safety, focusing on minimizing bias, validating models, and ensuring responsible AI deployment.
Collaborations
Owkin has established strategic partnerships with several leading biopharma companies such as Sanofi, BMS, and MSD. Through these collaborations, Owkin leverages its AI and data capabilities to enhance drug discovery and development. The company also works with top academic centers through its federated research network, granting access to research-grade patient data and supporting large-scale projects like the MOSAIC project, which aims to create the largest spatial omics atlas for cancer research.
Locations
Owkin operates in several major cities around the world, including Boston, New York, London, Paris, Nantes, Geneva, and Berlin. These locations enable the company to collaborate with a diverse range of biopharma firms, academic institutions, and healthcare providers, supporting its mission to integrate human and artificial intelligence for better drug and diagnostic outcomes on a global scale.